Get the Stockscreener App
7.71
4.47%
0.33
After Hours:
7.70
-0.010
-0.13%
Monte Rosa Therapeutics Inc stock is traded at $7.71, with a volume of 467.83K.
It is up +4.47% in the last 24 hours and up +60.63% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$7.38
Open:
$7.44
24h Volume:
467.83K
Relative Volume:
0.45
Market Cap:
$476.16M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-3.442
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
+2.80%
1M Performance:
+60.63%
6M Performance:
+96.68%
1Y Performance:
+54.20%
1-Day Range:
$7.435
$7.77
1-Week Range:
$7.235
$7.8712
52-Week Range:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
7.71 | 455.78M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics Forms Golden Cross, Signals Bullish Breakout Ahead - Markets Mojo
Will Monte Rosa Therapeutics Inc. see short term momentum2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com
Comparing Monte Rosa Therapeutics Inc. in custom built stock radarsJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
How high can Monte Rosa Therapeutics Inc. stock goShort Setup & Advanced Technical Analysis Signals - newser.com
Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Is Monte Rosa Therapeutics Inc a good long term investmentGeopolitical Risk Analysis & Consistent Double Returns - earlytimes.in
Monte Rosa Therapeutics Inc Stock Analysis and ForecastLarge Cap Stability Picks & Fast Profit Trading Ideas - earlytimes.in
Full technical analysis of Monte Rosa Therapeutics Inc. stockBuy Signal & Accurate Buy Signal Notifications - newser.com
Is Monte Rosa Therapeutics Inc. stock reversal real or fakeWatch List & Daily Chart Pattern Signals - newser.com
Monte Rosa Therapeutics Inc. stock trend forecastJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pallas Capital Advisors LLC Makes New $59,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - Defense World
Monte Rosa Therapeutics presents new CDK2 degradation inducers - BioWorld MedTech
Monte Rosa Is Building The ‘Next RNAi’ Through AI-Powered Molecular Glue Discovery - insights.citeline.com
Will Monte Rosa Therapeutics Inc. stock go up soonJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Sentiment analysis tools applied to Monte Rosa Therapeutics Inc.July 2025 Big Picture & Stepwise Entry and Exit Trade Signals - newser.com
Q3 EPS Forecast for Monte Rosa Therapeutics Cut by Analyst - MarketBeat
Aug EndMonth: Can Monte Rosa Therapeutics Inc disrupt its industryPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - خودرو بانک
Market Moves: Can Monte Rosa Therapeutics Inc. disrupt its industry2025 Retail Activity & Growth Oriented Trading Recommendations - خودرو بانک
Is a relief rally coming for Monte Rosa Therapeutics Inc. holders2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Pattern recognition hints at Monte Rosa Therapeutics Inc. upside2025 Analyst Calls & Reliable Volume Spike Alerts - newser.com
Is Monte Rosa Therapeutics Inc a potential multi baggerMarket Activity Report & Free High Return Stock Watch Alerts - خودرو بانک
Will Monte Rosa Therapeutics Inc benefit from seasonalityJuly 2025 Market Mood & Smart Swing Trading Alerts - خودرو بانک
Gains Report: Is Monte Rosa Therapeutics Inc stock a good pick for beginnersWeekly Loss Report & Daily Technical Stock Forecast Reports - khodrobank.com
Can momentum traders help lift Monte Rosa Therapeutics Inc.Earnings Miss & Daily Profit Focused Stock Screening - newser.com
EV Market: Why is Solid Biosciences Inc stock going up2025 Top Decliners & High Return Trade Opportunity Guides - khodrobank.com
Risk adjusted return profile for Monte Rosa Therapeutics Inc. analyzedQuarterly Portfolio Review & Weekly High Potential Alerts - newser.com
EV Market: Is Monte Rosa Therapeutics Inc stock a good pick for beginnersWeekly Investment Report & Low Drawdown Trading Strategies - خودرو بانک
Visual analytics tools that track Monte Rosa Therapeutics Inc. performance2025 Buyback Activity & Target Return Focused Picks - newser.com
Analyst Upgrade: Can Monte Rosa Therapeutics Inc lead its sector in growthWeekly Trade Summary & Reliable Price Action Trade Plans - خودرو بانک
Analysis Recap: Is Monte Rosa Therapeutics Inc stock a hidden gemMarket Risk Report & Intraday High Probability Alerts - خودرو بانک
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC - Seeking Alpha
Will Monte Rosa Therapeutics Inc. stock recover after recent dropWeekly Profit Analysis & AI Enhanced Trading Alerts - newser.com
Meme Stocks: Will Clene Inc. Equity Warrant benefit from government policyDip Buying & Reliable Price Breakout Signals - خودرو بانک
CEO Moves: Will Monte Rosa Therapeutics Inc. benefit from geopolitical trendsTreasury Yields & Proven Capital Preservation Methods - خودرو بانک
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):